Search Results - "Vanoli, Fiammetta"
-
1
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients
Published in Autoimmunity reviews (01-04-2020)“…Myastenia-Inflammatory Myopathy (MG-IM) association has been described in less than 50 cases, as isolated reports or in few case series. In most cases, MG and…”
Get full text
Journal Article -
2
Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up
Published in Journal of neurology (01-08-2021)“…Objectives To evaluate, in a prospective study, high-resolution ultrasound (HRUS) changes of nerve segments in chronic inflammatory demyelinating…”
Get full text
Journal Article -
3
Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
Published in Neurological sciences (01-05-2021)“…Introduction Myasthenia gravis (MG) is an autoimmune neuromuscular disease whose treatment encompasses acetylcholinesterase inhibitors, oral steroids, and…”
Get full text
Journal Article -
4
Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation
Published in Neurological sciences (01-02-2022)“…Aim Study of intraepidermal nerve fiber density (IENFD) by skin biopsy represents a promising tool in the evaluation of patients with ATTRv polyneuropathy…”
Get full text
Journal Article -
5
Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy
Published in Neurological sciences (01-12-2020)“…Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare form of treatable severe progressive sensory-motor and autonomic polyneuropathy…”
Get full text
Journal Article -
6
Complement Inhibition for the Treatment of Myasthenia Gravis
Published in ImmunoTargets and therapy (01-01-2020)“…Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80-90% of patients display…”
Get full text
Journal Article -
7
High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP
Published in Neurological sciences (01-05-2022)“…Introduction Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) remains a diagnostic challenge due to clinical, neurophysiological, and…”
Get full text
Journal Article -
8
Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy
Published in Biomedicines (09-06-2022)“…The complement system plays a key role in myasthenia gravis (MG). Anti-complement drugs are emerging as effective therapies to treat anti-acetylcholine…”
Get full text
Journal Article -
9
Current drug treatment of myasthenia gravis
Published in Current opinion in neurology (01-10-2023)“…Purpose of review Myasthenia Gravis (MG) is a rare neurological disorder affecting the neuromuscular junction. Clinical hallmarks are fatigability and weakness…”
Get full text
Journal Article -
10
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management
Published in Neurotherapeutics (01-04-2022)“…Summary Myasthenia gravis (MG) is a neurological autoimmune disorder characterized by muscle weakness and fatigue. It is a B cell–mediated disease caused by…”
Get full text
Journal Article -
11
Ravulizumab for the treatment of myasthenia gravis
Published in Expert opinion on biological therapy (04-03-2023)“…Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on…”
Get more information
Journal Article -
12
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
Published in Expert opinion on pharmacotherapy (02-09-2022)Get more information
Journal Article -
13
-
14
miRNA in spinal muscular atrophy pathogenesis and therapy
Published in Journal of cellular and molecular medicine (01-02-2018)“…Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by the selective death of lower motor neurons in the brain stem…”
Get full text
Journal Article -
15
Efgartigimod improves triple-negative myasthenia gravis
Published in Neurological sciences (01-03-2024)Get full text
Journal Article -
16
mi RNA in spinal muscular atrophy pathogenesis and therapy
Published in Journal of cellular and molecular medicine (01-02-2018)“…Abstract Spinal muscular atrophy ( SMA ) is an autosomal recessive neurodegenerative disease characterized by the selective death of lower motor neurons in the…”
Get full text
Journal Article -
17
Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center
Published in European journal of neurology (01-04-2024)“…Background and purpose Inhibition of the neonatal Fc receptor (FcRn) for IgG is a promising new therapeutic strategy for antibody‐mediated disorders. We report…”
Get full text
Journal Article -
18
Concordance between patient‐ and physician‐reported Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores
Published in Muscle & nerve (01-07-2023)“…Introduction/Aims Myasthenia gravis (MG) is a neuromuscular disease characterized by abnormal skeletal muscle fatiguability. The MG Activities of Daily Living…”
Get full text
Journal Article -
19
Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1
Published in Journal of cellular and molecular medicine (01-09-2015)“…Spinal muscular atrophy with respiratory distress (SMARD1) is an autosomal recessive neuromuscular disease caused by mutations in the IGHMBP2 gene, encoding…”
Get full text
Journal Article -
20
Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies
Published in Journal of neurology (01-02-2023)“…Objectives Immune-mediated necrotizing myopathy (IMNM) is the most severe idiopathic inflammatory myopathy (IIM) and early aggressive poly-immunotherapy is…”
Get full text
Journal Article